Products for Research Use Only
RegisterLogin

Vadadustat

CAT: 0957-S6490-01Size: 2 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0957-S6490-01Size:2 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Vadadustat (AKB-6548, B-506, PG-1016548) is a novel, titratable, oral HIF-PH inhibitor.
CAS Number
1000025-07-9
Synonyms
AKB-6548, B-506, PG-1016548
Target
HIF
Activity
Angiogenesis
Molecular Formula
C14H11ClN2O4
Storage Conditions
3 years -20°C powder

Chemical Information

Vadadustat

One of the most common symptoms of advanced renal disease is anemia, caused primarily by the inability of the kidney to respond to anemic conditions with a corresponding increase in [erythropoietin] (EPO) production. The treatment of anemia associated with chronic kidney disease (CKD) has traditionally involved the administration of exogenous erythropoiesis-stimulating agents (ESAs), such as [darbepoetin alfa], to counter the decrease in endogenous EPO production. While efficacious, the overuse of ESAs has been associated with cardiovascular complications, progression of CKD, and increases in overall mortality. A relatively new and alternative treatment option for patients with anemia associated with CKD is the use of small molecule inhibitors of hypoxia-inducible factor prolyl-hydroxylase (HIF-PH). These agents inhibit prolyl-hydroxylase domain oxygen sensors, mimicking hypoxic conditions and activating hypoxia-inducible factors. These transcription factors serve a multitude of roles, including the stimulation of erythropoiesis. Vadadustat is an orally administered inhibitor of HIF-PH with a safety and efficacy profile non-inferior to [darbepoetin alfa] for the treatment of anemia in patients with CKD undergoing dialysis. It was first approved in Japan in 2020, and in April 2023, it was approved by the EMA for the treatment of symptomatic anemia associated with CKD in adults on chronic maintenance dialysis. Vadadustat was approved by the FDA in March 2024.

CAS Number1000025-07-9
PubChem CID23634441
IUPAC Name2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
Molecular FormulaC14H11ClN2O4
Molecular Weight306.70
XLogP2.5
Topological Polar Surface Area99.5
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count5
Rotatable Bond Count4
Heavy Atom Count21
Formal Charge0
Complexity393
SMILES
C1=CC(=CC(=C1)Cl)C2=CC(=C(N=C2)C(=O)NCC(=O)O)O
InChI
InChI=1S/C14H11ClN2O4/c15-10-3-1-2-8(4-10)9-5-11(18)13(16-6-9)14(21)17-7-12(19)20/h1-6,18H,7H2,(H,17,21)(H,19,20)
InChIKey
JGRXMPYUTJLTKT-UHFFFAOYSA-N
Chemical Structure
2D Structure
2D structure of Vadadustat
CAS: 1000025-07-9
CID: 23634441
Formula: C14H11ClN2O4
MW: 306.70
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight306.70
XLogP32.5
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count5
Rotatable Bond Count4
Exact Mass306.0407345
Monoisotopic Mass306.0407345
Topological Polar Surface Area99.5 Ų
Heavy Atom Count21
Formal Charge0
Complexity393
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Alternative Products

CatalogName
B7960-100Vadadustat
CS-O-59123Vadadustat-d8
CS-O-47464Vadadustat 13C215N
A16794-5Vadadustat 5mg
HY-101277RVadadustat (Standard)
A16794-50Vadadustat 50mg
A16794-2Vadadustat 2mg
CS-O-60015Vadadustat-d5

Popular Products